Novartis Ag (NVSEF) Equity Income (2009 - 2026)

Novartis Ag has disclosed Equity Income across 16 years of filings, most recently posting -$3.0 million for Q1 2026.

• Equity Income for Q1 2026 came in at -$3.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$12.0 million (changed 0.0% YoY), and the FY2025 annual result was -$12.0 million, up 68.42% from the prior year.
• Equity Income came in at -$3.0 million for Q1 2026 at Novartis Ag, down from -$2.0 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of -$2.0 million in Q1 2022 to a low of -$29.0 million in Q1 2024.
• The 5-year median for Equity Income is -$3.0 million (2022), against an average of -$4.8 million.
• Across the five-year window, Equity Income tumbled 1350.0% in 2024 and jumped 89.66% in 2025, its largest moves.
• Novartis Ag's Equity Income stood at -$3.0 million in 2022, then sank by 100.0% to -$6.0 million in 2023, then surged by 50.0% to -$3.0 million in 2024, then surged by 33.33% to -$2.0 million in 2025, then slumped by 50.0% to -$3.0 million in 2026.
• The last three Equity Income figures came in at -$3.0 million (Q1 2026), -$2.0 million (Q4 2025), and -$4.0 million (Q3 2025), per Business Quant data.